VIDEO: New data on paclitaxel plus trastuzumab in early HER2-positive breast cancer
Click Here to Manage Email Alerts
Adjuvant paclitaxel and trastuzumab continued to appear effective after 10 years of follow up among patients with small node-negative, HER2-positive breast cancer, according to data presented at San Antonio Breast Cancer Symposium.
“With 10 years of follow up, there was a 91% invasive disease-free survival rate, and there was a 96% recurrence-free interval, with only six distant events seen out of 406 patients treated on this trial,” Sara M. Tolaney, MD, MPH, chief of the division of breast oncology at Susan F. Smith Center for Women's Cancers in the Dana Farber Cancer Institute, told Healio. “I think these data really suggest that the regimen continues to remain a very acceptable treatment option for patients who do have predominantly stage I HER2-positive cancers.”
Previously, researchers had published 3-year and 7-year follow-up results from this trial.
Tolaney also discussed data from the ATEMPT trial, which included the 5-year results from the trial assessing adjuvant trastuzumab emtansine (T-DM1) compared with paclitaxel plus trastuzumab in patients with stage I HER2-positive breast cancer.
She said the findings suggest “very few recurrences with a year of T-DM1, but also showed that the HER2DX [Reveal Genomics] assay was able to help predict prognosis in this early-stage population. “Hopefully in the future, we’ll be able to really personalize care for these stage I HER2-positive patients,” Tolaney said.
References:
Tolaney S, et al. Adjuvant Paclitaxel and Trastuzumab trial (APT) for node-negative, human epidermal growth factor receptor 2–positive (HER2+) breast cancer: final 10-year results and correlative analyses. Presented at: San Antonio Breast Cancer Symposium; Dec. 6-10, 2022.
Tarantino P, et al. Adjuvant trastuzumab emtansine versus paclitaxel plus trastuzumab for stage I HER2+ breast cancer: 5-year results and correlative analyses from ATEMPT. Presented at: San Antonio Breast Cancer Symposium; Dec. 6-10, 2022.
Collapse
Read more about
Click Here to Manage Email Alerts